Study reveals extremely low detection of SARS-CoV-2 on surfaces in oncology facilities
Researchers from Rutgers Cancer Institute of New Jersey, the state s only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.
The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor. Andrew M. Evens, DO, MSc, FACP, associate director for clinical services and director of the Lymphoma Program at Rutgers Cancer Institute and medical director of the oncology service line at RWJBarnabas Health, is senior author of the work, which has been published in the February 18 online edition of
Researchers from Rutgers Cancer Institute of New Jersey, the state's only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility.
Researchers from Rutgers Cancer Institute of New Jersey, the state s only National Cancer Institute-designated Comprehensive Cancer Center, evaluated the frequency of SARS-CoV-2, the virus that causes COVID-19, on various environmental surfaces in outpatient and inpatient hematology/oncology settings located within Rutgers Cancer Institute and Robert Wood Johnson University Hospital, an RWJBarnabas Health facility. The study revealed extremely low detection of SARS-CoV-2 on environmental surfaces across multiple outpatient and inpatient oncology areas, including an active COVID-19 floor.
Validation of Novel Prognostic Index May Better Inform Burkitt Lymphoma Treatment
Research by Rutgers Cancer Institute of New Jersey and RWJBarnabas Health researcher and international collaborators can help identify prognosis and stratify risk
News provided by
Share this article
(PRNewsfoto/Rutgers Cancer Institute of New Jersey and RWJBarnabas Health)
NEW BRUNSWICK, N.J., Jan. 28, 2021 /PRNewswire/ Rutgers Cancer Institute of New Jersey, a leader in cutting-edge clinical trials and a National Cancer Institute- designated Comprehensive Cancer Center, together with RWJBarnabas Health, today announced the publication of research that has identified and validated the novel Burkitt Lymphoma International Prognostic Index (BL-IPI) in patients with this rare, high-grade B-cell lymphoma that is often studied in trials with small sample sizes. The research from the Burkitt Lymphoma International Prognostic Index Consortium is published in the January 2021 online issue of